These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3322358)

  • 1. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.
    Rustin MH; Almond NE; Beacham JA; Brooks RJ; Jones DP; Cooke ED; Dowd PM
    Br J Dermatol; 1987 Dec; 117(6):751-8. PubMed ID: 3322358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study].
    Madsen JL; Hvidt S
    Ugeskr Laeger; 1984 Sep; 146(36):2695-7. PubMed ID: 6393495
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enalapril in Raynaud's phenomenon.
    Janini SD; Scott DG; Coppock JS; Bacon PA; Kendall MJ
    J Clin Pharm Ther; 1988 Apr; 13(2):145-50. PubMed ID: 2839529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International study of ketanserin in Raynaud's phenomenon.
    Coffman JD; Clement DL; Creager MA; Dormandy JA; Janssens MM; McKendry RJ; Murray GD; Nielsen SL
    Am J Med; 1989 Sep; 87(3):264-8. PubMed ID: 2672807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
    Sunderland GT; Belch JJ; Sturrock RD; Forbes CD; McKay AJ
    Clin Rheumatol; 1988 Mar; 7(1):46-9. PubMed ID: 3044673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
    Kahan A; Amor B; Menkès CJ; Weber S; Guérin F; Degeorges M
    Angiology; 1987 Apr; 38(4):333-7. PubMed ID: 3555175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A; McCans J; Willan AR; Ford PM
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A; Amor B; Menkès CJ
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
    Mohrland JS; Porter JM; Smith EA; Belch J; Simms MH
    Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome.
    Rustin MH; Grimes SM; Kovacs IB; Cooke ED; Bowcock SA; Sowemimo-Coker SO; Turner P; Kirby JD
    Eur J Clin Pharmacol; 1984; 27(1):61-5. PubMed ID: 6386490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of Raynaud's syndrome with captopril].
    Trübestein G; Wigger E; Trübestein R; Ludwig M; Wilgalis M; Stumpe KO
    Dtsch Med Wochenschr; 1984 Jun; 109(22):857-60. PubMed ID: 6373219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effect of topical minoxidil on digital blood flow in patients with Raynaud's phenomenon.
    Whitmore SE; Wigley FM; Wise RA
    J Rheumatol; 1995 Jan; 22(1):50-4. PubMed ID: 7699682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.